- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02145156
Educational Intervention to Minimize Disparities in Humanpapillomavirus Vaccination (HPV)
Educational Intervention to Minimize Disparities in HPV Vaccination
The purpose of this study is to evaluate an innovative approach to improving HPV vaccination among the Hispanic population. The clinical objectives/aims of this HPV educational intervention project are to determine:
- The number of young adults and adolescents in each arm who received any dose of the HPV vaccine during the study period,
- The number of young adults and adolescents in each arm who initiated the HPV vaccine series during the study period,
- The number of young adults and adolescents in each arm who initiated but did not complete the HPV vaccine series during the study period,
- The number of young adults and adolescents in each arm, among all eligible, who completed the HPV vaccine series during the study period,
- The number of young adults and adolescents in each arm who completed the HPV vaccine series during the study period, among those who initiated the series at study start, and
- The number of young adults and adolescents in each arm who completed the HPV vaccine series among those who initiated the series during the study period.
The implementation of this educational intervention in clinic waiting rooms is intended to assist primary care providers in communicating HPV vaccine awareness and education to parents and patients in a culturally tailored format.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
While HPV infection is nearly ubiquitous among the sexually active population, the morbidity and mortality from HPV-related diseases disproportionately affects minorities and the poor. Hispanic women are at particularly high risk as they have the highest rates of invasive cervical cancer when compared to all other racial or ethnic groups in the U.S. Initiating the 3-dose HPV vaccination series is more common among Hispanic adolescents than whites, but series completion has been lowest among Hispanic populations.
To understand barriers to HPV vaccination and to provide insight into ways in which an existing educational intervention should be modified for a Hispanic population, the investigators conducted focus groups among Hispanic parents and Latina young adults. All groups reported vaccine cost, access to insurance, and a general lack of awareness and/or understanding of either HPV or the vaccine as barriers. All groups also wanted substantially more "general" information about both HPV and the vaccine in order to make informed vaccination decisions. The educational intervention was generally well received but there were universal suggestions from all the groups to provide additional basic information about HPV infection, to add information about the vaccine for boys/young men, and to modify the color scheme and logo to make it more eye-catching and pleasing.
This current phase of the project will be comprised of real world testing of an iPad-based educational intervention about HPV, "Combatting HPV Infection and Cancer" (CHICOS) that has been revised and developed per focus group feedback to target the Hispanic population.
By providing information that patients and parents have clearly indicated they want in a way that is culturally sensitive and meaningful and also individually personalized, the investigators hope to improve HPV vaccination rates.
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
Colorado
-
Aurora, Colorado, Förenta staterna, 80045
- University of Colorado Denver
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Parents of an adolescent between the ages of 9-17; OR a young adult patient between the ages of 18-26;
- Adolescent/young adult has not yet received all three doses of the HPV vaccine.
- Parent/young adult can read and converse in either English or Spanish
Exclusion Criteria:
- Age <18,
- Prisoners
- Decisionally challenged subjects
- Those who cannot read and converse in either English or Spanish
- Those who have received all 3 doses of the HPV vaccine
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Hälsovårdsforskning
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Övrig: Untailored Intervention
Intervention: untailored educational materials.
In this arm, patients will view educational information on the iPad that is not responsive to their baseline questionnaire answers.
|
The untailored intervention will present educational information on the iPad that is not responsive to participants' baseline questionnaire answers and instead is derived directly from the HPV "Vaccine Information Sheet" that has been created by the Centers for Disease Control and Prevention.
|
Experimentell: Tailored intervention
Intervention: tailored educational materials.
In this arm, participants will complete a baseline survey on an iPad, view a series of educational webpages on the iPad, and complete a brief post intervention survey.
|
The tailored intervention will use participants' baseline survey responses to generate tailored educational messages about the HPV vaccine.
These educational messages will reflect the top concerns indicated by the participant about the HPV vaccine.
Additional tailoring will occur in the form of images matched to self-reported race and age, and using participants' first name in the information presented.
|
Övrig: Usual Care
Intervention: survey-only.
Participants in the usual care arm will not view any educational materials or complete the baseline survey.
|
Those in the usual care arm will be provided with a paper version of the Post Intervention Survey.
This will be provided to participants after their clinic visit is completed.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Number of Young Adults Who Received Any Dose of the HPV Vaccine During the Study Period
Tidsram: 16 months
|
This outcome describes the number of young adult participants between the ages of 18-26 who received any dose of the HPV vaccine during the study period.
|
16 months
|
Number of Young Adults Who Initiated the HPV Vaccine Series During the Study Period
Tidsram: 16 months
|
This outcome describes the number of young adult participants between the ages of 18-26 who had 0 doses of the HPV vaccine at study enrollment and received at least one dose during the study period.
|
16 months
|
Number of Young Adults Who Initiated But Did Not Complete the HPV Vaccine Series During the Study Period
Tidsram: 16 months
|
This outcome describes the number of young adult participants between the ages of 18-26 who had 0 doses of the HPV vaccine at study enrollment and did not complete the vaccine series during the study period.
|
16 months
|
Number of Young Adults, Among All Eligible, Who Completed the HPV Vaccine Series During the Study Period
Tidsram: 16 months
|
This outcome describes the number of young adult participants between the ages of 18-26 who had 0, 1 or 2 doses of the HPV vaccine at study enrollment and completed the vaccine series during the study period.
|
16 months
|
Number of Young Adults Who Completed the HPV Vaccine Series During the Study Period, Among Those Who Initiated the Series at Study Start
Tidsram: 16 months
|
This outcome describes the number of young adult participants between the ages of 18-26 who had 1 or 2 doses of the HPV vaccine at study enrollment and completed the vaccine series during the study period.
|
16 months
|
Number of Young Adults Who Completed the HPV Vaccine Series Among Those Who Initiated the Series During the Study Period
Tidsram: 16 months
|
This outcome describes the number of young adult participants between the ages of 18-26 who had 0 doses of the HPV vaccine at study enrollment and completed the vaccine series during the study period.
|
16 months
|
Number of Adolescents Who Received Any Dose of the HPV Vaccine During the Study Period
Tidsram: 16 months
|
This outcome describes the number of adolescent participants between the ages of 9-17 who received any dose of the HPV vaccine during the study period.
|
16 months
|
Number of Adolescents Who Initiated the HPV Vaccine Series During the Study Period
Tidsram: 16 months
|
This outcome describes the number of adolescent participants between the ages of 9-17 who had 0 doses of the HPV vaccine at study enrollment and received at least one dose during the study period.
|
16 months
|
Number of Adolescents Who Initiated But Did Not Complete the HPV Vaccine Series During the Study Period
Tidsram: 16 months
|
This outcome describes the number of adolescent participants between the ages of 9-17 who had 0 doses of the HPV vaccine at study enrollment and did not complete the vaccine series during the study period.
|
16 months
|
Number of Adolescents, Among All Eligible, Who Completed the HPV Vaccine Series During the Study Period
Tidsram: 16 months
|
This outcome describes the number of adolescent participants between the ages of 9-17 who had 0, 1 or 2 doses of the HPV vaccine at study enrollment and completed the vaccine series during the study period.
|
16 months
|
Number of Adolescents Who Completed the HPV Vaccine Series During the Study Period, Among Those Who Initiated the Series at Study Start
Tidsram: 16 months
|
This outcome describes the number of adolescent participants between the ages of 9-17 who had 1 or 2 doses of the HPV vaccine at study enrollment and completed the vaccine series during the study period.
|
16 months
|
Number of Adolescents Who Completed the HPV Vaccine Series Among Those Who Initiated the Series During the Study Period
Tidsram: 16 months
|
This outcome describes the number of adolescent participants between the ages of 9-17 who had 0 doses of the HPV vaccine at study enrollment and completed the vaccine series during the study period.
|
16 months
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Amanda F Dempsey, MD, PhD, MPH, University of Colorado, Denver
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- 14-0402
- PCORI 1455 (Annat bidrag/finansieringsnummer: Patient Centered Outcomes Research Institute)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på HPV Vaccination Status
-
Memorial Sloan Kettering Cancer CenterHackensack Meridian Health; The City College of New YorkAktiv, inte rekryterandeHPV-vaccinationFörenta staterna
-
Yale UniversityNational Cancer Institute (NCI)Avslutad
-
Yasemin ATEŞEYANAvslutadHPV-VACCINATIONKalkon
-
University of Alabama at BirminghamRekryteringHPV-vaccinationFörenta staterna
-
The University of Texas Health Science Center,...AvslutadÖka upptaget av HPV-vaccination | Fördröj sexuell debutFörenta staterna
-
Lancaster UniversityPennine Acute Hospitals NHS TrustAvslutadStatus för vaccination/immuniseringStorbritannien
-
University of UtahNational Cancer Institute (NCI); Kaiser Permanente; University of Arizona; Sea...Har inte rekryterat ännuVaccin tveksamhet | HPV-vaccination | Vaccinvägran | Vaccin; Upptag | Vaccination; Slutförande av serienFörenta staterna
-
University Hospital, BrestAvslutadLivmoderhalscancer | Vaccinförebyggbar sjukdom | HPV | HPV-vaccination | Cervikal skadaFrankrike
-
University Hospital, BrestAvslutadLivmoderhalscancer | HPV-vaccination | Pap Smear | Vaccination ikappFrankrike
-
Cedars-Sinai Medical CenterUniversity of California, Los AngelesOkändHälsoutbildning | Mänskligt papillomvirus | HPV-vaccination
Kliniska prövningar på Tailored educational materials
-
University of WashingtonAktiv, inte rekryterandeÅldrande | Oavsiktligt fallFörenta staterna
-
Duke UniversityNational Institute of Mental Health (NIMH)AvslutadSchizofrenispektrum och andra psykotiska störningar | Psykiska störningar, allvarligaTanzania
-
University of UlsterQueen's University, Belfast; University of Bristol; Marie Curie Hospice,...Avslutad
-
University of Sao PauloAvslutadÅngest | Malocklusion | Prognatism | MikrognatismBrasilien
-
Maisonneuve-Rosemont HospitalPfizerAvslutad
-
Ziauddin UniversityUniversiti Sains MalaysiaHar inte rekryterat ännuGingivit | PlackPakistan
-
Wayne State UniversityNational Institute on Minority Health and Health Disparities (NIMHD)Har inte rekryterat ännuTyp 1-diabetes | FamiljerelationerFörenta staterna
-
Michael E. DeBakey VA Medical CenterBaylor College of MedicineOkänd
-
University of British ColumbiaChild and Family Research InstituteAvslutad
-
Massachusetts General HospitalGordon and Betty Moore FoundationAvslutadAvancerad cancerFörenta staterna